Medical Affairs at the Centre of Life Sciences Innovation

In today’s challenging business environment, many innovative life sciences companies are raising questions about the return on investment of internal resources and external expenditures. These
questions are now being asked of Medical Affairs Leaders. It is very challenging to measure Medical Affairs ‘value’ in this way, and we see many instances of Medical Affairs investments being
constrained in light of general budgetary pressures. We argue that this is a short-sighted and potentially hazardous trend as we believe that Medical Affairs capabilities must evolve to be at the
centre of life sciences companies’ therapeutic innovation, product development and stakeholder interactions.